Previous close | 10.80 |
Open | 10.82 |
Bid | 10.80 x 100 |
Ask | 10.82 x 100 |
Day's range | 10.81 - 10.82 |
52-week range | 10.00 - 12.20 |
Volume | |
Avg. volume | 16,680 |
Market cap | 73.939M |
Beta (5Y monthly) | 0.01 |
PE ratio (TTM) | 49.14 |
EPS (TTM) | 0.22 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
In this article, we discuss Farallon Capital: a global and diversified hedge fund and its top stock picks. If you want to skip our detailed analysis of these stocks, go directly to the Top 5 Stock Picks of Farallon Capital. Risk arbitrage or merger arbitrage is one of the most popular strategies that hedge funds […]
NEW YORK & VERO BEACH, Fla., August 11, 2023--HDL Therapeutics, Inc. ("HDL Therapeutics"), a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy the Plasma Delipidation System (PDS-2™ System) for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia (HoFH), has signed a definitive merger agreement with Swiftmerge Acquisition Corp. (NASDAQ: IVCP) ("Swiftmerge"), a special purpose acquisition company with a disruptive consumer
Key Insights Significantly high institutional ownership implies Swiftmerge Acquisition's stock price is sensitive to...